stock-detail (DRNA)

Oncology Corporate Profile

Company Description

This company does not have any commercial products

This company does not have any pipeline products

Recent News Headlines

4/24/2017 12:17 pm

4/24/2017 12:17 pm

4/24/2017 12:17 pm

4/24/2017 12:17 pm

4/24/2017 12:17 pm

4/20/2017 06:17 am

4/20/2017 06:17 am

4/20/2017 06:17 am

4/20/2017 06:17 am

4/20/2017 06:17 am

4/12/2017 06:17 am

4/12/2017 06:17 am

4/12/2017 06:17 am

4/12/2017 06:17 am

4/12/2017 06:17 am

Dicerna Secures $70 Million in Convertible Preferred Stock Financing

3/30/2017 08:00 pm

[Business Wire] - Dicerna Pharmaceuticals, Inc. , a leading developer of investigational ribonucleic acid interference therapeutics, today announced that it has signed a stock purchase agreement with a syndicate of current and new investors, led by Bain Capital Life Sciences, for the sale of redeemable convertible preferred stock for gross proceeds of $70.0 million.

Dicerna Reports Fourth Quarter and Full Year 2016 Financial and Operational Results

3/30/2017 08:00 pm

[Business Wire] - Dicerna Pharmaceuticals, Inc. , a leading developer of investigational ribonucleic acid interference therapeutics, today reported financial and operational results for the fourth quarter and full year ended December 31, 2016.

Dicerna Pharmaceuticals to Present at the BioCentury 24th Annual Future Leaders in the Biotech Industry Conference

3/27/2017 08:00 pm

[Business Wire] - Dicerna Pharmaceuticals, Inc. , a leading developer of investigational ribonucleic acid interference therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present a corporate update at the BioCentury 24th Annual Future Leaders in the Biotech Industry Conference on Friday, April 7, 2017, at 3:00 p.m.

Dicerna to Report Fourth Quarter and Full Year 2016 Financial Results and Host Conference Call on March 30, 2017

3/23/2017 08:00 pm

[Business Wire] - Dicerna Pharmaceuticals, Inc. , a leading developer of investigational ribonucleic acid interference therapeutics, today announced that the Company will release its fourth quarter and full year 2016 financial results after market close on Thursday, March 30, 2017.